Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance.
Tasneem Khanam, Sarah Sandmann, Jochen Seggewiss...
https://pubmed.ncbi.nlm.nih.gov/33152759/Actively Recruiting
Led by University Hospital Muenster · Updated on 2026-05-06
683
Participants Needed
228
Research Sites
N/A
Total Duration
This research aims to improve treatment for children and adolescents newly diagnosed with lymphoblastic lymphoma. The trial is a large, international, randomized clinical study involving multiple countries and specialized centers. It focuses on whether using dexamethasone instead of prednisone during the induction phase can reduce relapses in the central nervous system CNS, and for high-risk patients, whether an intensified treatment improves event-free survival compared to standard therapy. Participants are grouped by risk level based on disease characteristics like CNS involvement and genetic markers. All patients first receive a prednisone prephase, then are randomized to either standard induction with prednisone or experimental induction with dexamethasone. Treatment phases include consolidation, extra-compartment phases adjusted by risk group, reintensification for some groups, and maintenance therapy lasting up to 24 months. Patients with CNS involvement receive intensified intrathecal therapy without cranial irradiation. High-risk patients may undergo a second randomization to receive either standard or intensified treatment during later phases. During the study, patients undergo various treatments including chemotherapy drugs such as cyclophosphamide, methotrexate, and PEG asparaginase. Researchers monitor disease relapse involving the CNS and measure event-free survival over a maximum of 7.25 years. Secondary assessments include overall survival, treatment-related toxicity and mortality, adverse events, and molecular markers. The trial involves ongoing follow-up for safety and effectiveness outcomes throughout the study period, which can last several years.
CONDITIONS
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
B
Birgit Burkhardt, Prof. Dr. Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital Muenster
Lead Sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Initial treatment phase duration varies by protocol
Participants receive a cytoreductive prephase with prednisone followed by induction therapy. Depending on risk group and randomization, induction therapy includes either prednisone (standard arm) or dexamethasone (experimental arm).
Multiple visits during induction phase as part of treatment
Duration - Following induction, part of total 24 months therapy duration
After induction, participants undergo consolidation therapy and extra-compartment phases. High risk participants may receive intensified extra-compartment treatment and additional doses of PEG asparaginase depending on randomization.
Regular visits for chemotherapy administration and monitoring
Duration - Part of total 24 months therapy duration
Participants in certain risk groups receive a reintensification phase following extra-compartment therapy to further reduce disease burden.
Visits scheduled during reintensification as per protocol
Duration - Up to 24 months total therapy duration including previous phases
Participants continue with maintenance therapy to sustain remission and prevent relapse, completing a total therapy duration of 24 months.
Periodic visits during maintenance therapy for treatment and monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Have more questions? Get in touch with our team for quick support
Tasneem Khanam, Sarah Sandmann, Jochen Seggewiss...
https://pubmed.ncbi.nlm.nih.gov/33152759/University Hospital Muenster
Lead Sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborating Sponsor